

February 10, 2026

Listing Department
BSE LIMITED
P J Towers, Dalal Street,
Mumbai-400001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C/1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai-400051

Code: ZYDUSLIFE

Re.: **Newspaper publication**

Ref.: **Disclosure under regulation 30 read with regulations 33 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

Dear Sir / Madam,

Pursuant to the provisions of regulation 30 read with regulations 33 and 47 of the Listing Regulations, please find attached the newspaper cutting with regard to publication of unaudited financial results for the quarter / nine months ended on December 31, 2025, in Financial Express on February 10, 2026.

Please find the same in order.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

Encl.: As above





Dedicated To Life

Zydus Lifesciences Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),

Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CTIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025

Sr. No.	Particulars	INR Million					
		Quarter ended			Nine Months ended		Year ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	68,645	61,232	52,691	195,614	167,136	232,415
2	Net profit for the period before exceptional items and tax	14,383	17,216	11,841	50,805	43,547	62,463
3	Net profit for the period after exceptional items but before tax	13,534	16,874	11,841	49,614	43,547	60,267
4	Net Profit for the period from continuing operations	10,421	12,586	10,238	37,675	33,546	45,255
5	Profit after tax from discontinued operations	-	-	(3)	-	-	-
6	Net profit for the period after tax and non-controlling interest	10,421	12,586	10,235	37,675	33,546	45,255
7	Total comprehensive income for the period after tax and non-controlling interest	10,213	9,841	9,804	34,771	32,774	44,257
8	Paid-up equity share capital (Face value Re. 1/-)	1,006	1,006	1,006	1,006	1,006	1,006
9	Other equity	-	-	-	-	-	238,525
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	10.36	12.51	10.18	37.44	33.34	44.97
b	Diluted (Rs.)	10.36	12.51	10.18	37.44	33.34	44.97
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	10.36	12.51	10.17	37.44	33.34	44.97
b	Diluted (Rs.)	10.36	12.51	10.17	37.44	33.34	44.97

Note:

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results, alongwith the Limited Review Reports are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com] and can also be accessed by scanning the following QR Code:



By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Date: February 9, 2026
Place: North Goa



Dedicated To Life

Zydus Lifesciences Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),

Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025

Sr. No.	Particulars	INR Million					
		Quarter ended			Nine Months ended		Year ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	68,645	61,232	52,691	195,614	167,136	232,415
2	Net profit for the period before exceptional items and tax	14,383	17,216	11,841	50,805	43,547	62,463
3	Net profit for the period after exceptional items but before tax	13,534	16,874	11,841	49,614	43,547	60,267
4	Net Profit for the period from continuing operations	10,421	12,586	10,238	37,675	33,546	45,255
5	Profit after tax from discontinued operations	-	-	(3)	-	-	-
6	Net profit for the period after tax and non-controlling interest	10,421	12,586	10,235	37,675	33,546	45,255
7	Total comprehensive income for the period after tax and non-controlling interest	10,213	9,841	9,804	34,771	32,774	44,257
8	Paid-up equity share capital (Face value Re. 1/-)	1,006	1,006	1,006	1,006	1,006	1,006
9	Other equity	-	-	-	-	-	-
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)	-	-	-	-	-	238,525
a	Basic (Rs.)	10.36	12.51	10.18	37.44	33.34	44.97
b	Diluted (Rs.)	10.36	12.51	10.18	37.44	33.34	44.97
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)	-	-	-	-	-	-
a	Basic (Rs.)	10.36	12.51	10.17	37.44	33.34	44.97
b	Diluted (Rs.)	10.36	12.51	10.17	37.44	33.34	44.97

Note:

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The results, alongwith the Limited Review Reports are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com] and can also be accessed by scanning the following QR Code:



By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Date: February 9, 2026

Place: North Goa